Ganetespib has demonstrated its efficacy not only in monotherapy, but also in combination with other drugs in various cancer types driven by different oncogenic mutations such as mutant EGFR [268] and KRAS mutant NSCLC [269,270,271]. Here, KRAS is linked to non-small cell lung carcinoma.